Fresenius Kabi $4.3 billion acquisition of Akorn

Overview:

• German pharmaceutical and healthcare device company Fresenius Kabi has acquired US-based generic drug producer Akorn in a $4.3 billion deal.
• Akorn was sold by German pharmaceutical company the Merck Group.
• The purchase also includes $450 million of debt.
• The US headquarters for both companies are located in Illinois.
• The transaction is expected to close by the beginning of 2018.

Kurt Stumpo - Journalist